Kartashova Elena Aleksandrovna (RU),Карташова Елена Александровна (RU),Sarvilina Irina Vladislavovna (RU),Сарвилина Ирина Владиславовна (RU),Kastanayan Aleksandr Alesianosovich (RU),Кастанаян Александ
申请号：
RU2019123706
公开号：
RU0002726071C1
申请日:
2019.07.22
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to therapy, cardiology and clinical pharmacology, and can be used for treating isolated degree 1 systolic arterial hypertension (ISAH) in patients of early period of old age - 65–74 years and senile age - older than 75 years. In all patients with ISAH 1 degree of the above age, molecular diagnostics of blood plasma is performed and the level of expression of cathepsin G, myeloperoxidase, induced hypoxia Ia, hyaluronidase, kininogen-1, pyruvate kinase and subunit of alpha ATP-synthase. In the senile age, the level of expression of apolipoprotein D, a transforming growth factor beta-1, fibulin-5 is additionally determined. If observing the presence of a level of expression of cathepsin G equal to 3.5 ng/ml or more, myeloperoxidase, equal to 23 Un/ml or more, hypoxia of the induced factor Ia equal to 280 pg/ml or more, hyaluronidase equal to 9 mE/l or more, kininogen-1 equal to 85 ng/ml or more, pyruvate kinase equal to 10 Un/ml or more, and subunit of alpha ATP-synthase equal to 60 pg/ml or more, apolipoprotein D, equal to or greater than 30 ng/ml, transforming growth factor beta-1 equal to 900 pg/ml or more, fibulin-5 equal to 250 pg/ml or more, therapy is ensured by prescribing a combination of the blocker to the angiotensin II receptor and the slow calcium channel blocker.EFFECT: method provides reducing the dose of hypotensive medicines, increasing the effectiveness and safety of the treatment while reducing the economic costs of the pharmacotherapy by using the antihypertensive drugs taking into account the molecular profile of the blood plasma in each patient.1 cl, 2 exИзобретение относится к медицине, а именно к терапии, кардиологии и клинической фармакологии, и может быть использовано для лечения изолированной систолической артериальной гипертензии (ИСАГ) 1 степени у пациентов раннего периода старости - 65-74 года и старческого возраста - старше 75 лет. У всех пациентов с ИСАГ 1 степени указанного
